Drugs / CS2009
Trials 1 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1/2 | NCT06741644 | Feb 2025 → Jan 2027 expected | cancer | CStone Pharmaceuticals | Recruiting | No outcome recorded |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CS2009 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT06741644 ↗ |
| Route | Intravenous | “CS2009 will be administered via intravenous (IV) infusion” NCT06741644 ↗ |
| Target | VEGFA | “CS2009, a Tri-specific Antibody Targeting PD-1/VEGFA/CTLA-4” NCT06741644 ↗ |